A GLP-1 microdosing chart shows weekly dose ranges starting below the standard FDA-approved starting dose, typically 0.05 to 0.125 mg for semaglutide and 0.5 to 1.25 mg for tirzepatide, increasing gradually based on individual tolerance. Microdosing is an off-label approach determined at the provider’s discretion; it is not part of the FDA-approved titration schedule for either medication. All doses referenced here apply to compounded GLP-1 medications sourced from a 503A FDA-regulated pharmacy with a valid prescription.
You found the right starting dose, and for many people that is not the first one they were prescribed. A lot of patients come to GLP-1 microdosing after a rough few weeks at standard doses: nausea that made it hard to get through the workday, fatigue that would not lift, or GI symptoms that pushed them to quit. Others start there intentionally, wanting a gentler on-ramp to treatment.
Whatever brought you here, the question is the same: what does the dosing actually look like, week by week?
This chart lays out reference dose ranges for both semaglutide and tirzepatide microdosing schedules. It is not a prescription. Your provider sets your dose based on your health history, your body’s response, and your goals. But understanding the general framework helps you have a more productive conversation with your medical team.
What Is GLP-1 Microdosing?
GLP-1 microdosing means starting at a dose lower than the standard FDA-approved starting point and titrating up more slowly than the approved protocol calls for. For semaglutide, the approved starting dose is 0.25 mg weekly. For tirzepatide, it is 2.5 mg weekly. A microdosing approach typically begins at a fraction of those amounts.
The reasoning is practical. A 2017 study published in Diabetes, Metabolic Syndrome and Obesity found that GI side effects were among the leading reasons patients stopped GLP-1 treatment before it had a chance to work. Starting lower and moving up more gradually gives the body time to adjust, and for many patients, that means staying on treatment long enough to see real results.
Microdosing is off-label. No standardized protocol exists in the FDA prescribing guidelines. A licensed provider determines whether it is appropriate for you and builds your schedule from there.
GLP-1 Microdosing Dosage Chart: Semaglutide vs. Tirzepatide
The table below shows illustrative weekly dose ranges for both medications. Your provider sets your actual dose based on your health history and individual response. These are reference ranges for understanding the framework, not a self-directed protocol to follow independently.
| Phase | Semaglutide (weekly) | Tirzepatide (weekly) | Notes |
|---|---|---|---|
| Weeks 1-2 | 0.05-0.125 mg | 0.5-1.0 mg | Starting range; monitor tolerance closely |
| Weeks 3-4 | 0.125-0.25 mg | 1.0-1.5 mg | Increase only if side effects are minimal |
| Weeks 5-8 | 0.25-0.5 mg | 1.5-2.5 mg | Approaching standard starting dose range |
| Weeks 9-12 | 0.5-0.75 mg | 2.5-3.75 mg | Provider adjusts based on appetite control and tolerance |
| Week 13+ | 0.75-1.0 mg or individualized | 3.75-5.0 mg or individualized | Titrate toward therapeutic goal dose |
| FDA standard starting dose | 0.25 mg | 2.5 mg | Reference per FDA prescribing information |
| FDA max approved dose | 2.4 mg (Wegovy) | 15 mg (Zepbound) | For reference only |
Note: These ranges reflect commonly used compounded microdosing approaches. Your provider may prescribe doses outside this range. Reference: FDA prescribing information for semaglutide (NDA 209637) and tirzepatide (NDA 217806).
Semaglutide Microdosing: What the Weekly Schedule Looks Like
Semaglutide activates GLP-1 receptors, which slow gastric emptying, reduce appetite, and support glucose regulation. The STEP 1 trial, published in the New England Journal of Medicine in 2021, found that semaglutide at 2.4 mg weekly produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity.
At microdoses, the appetite suppression is subtler and side effects are typically far milder. The trade-off is a longer path to significant weight loss.
A semaglutide microdosing schedule in practice looks like this: start at 0.05 to 0.125 mg in the first two weeks, hold at that level until any initial GI symptoms settle, then increase by small increments every two to four weeks based on how your body is responding. Most people using this approach take three to six months to reach what would be considered a standard starting dose of 0.25 mg.
Some providers also split the weekly dose into two smaller injections given three to four days apart. This can help smooth out concentration peaks and troughs. It is another off-label variation your provider can evaluate for your situation specifically.
Tirzepatide Microdosing: What the Weekly Schedule Looks Like
Tirzepatide activates both GLP-1 and GIP receptors, making it a dual agonist. The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, found that tirzepatide at 15 mg weekly produced an average weight loss of up to 22.5% over 72 weeks in adults with obesity.
Because tirzepatide acts on two pathways, some patients find it more potent from the start. That potency can also mean more noticeable side effects in the early weeks, which is part of why a microdosing approach appeals to people who have had difficulty tolerating standard-dose GLP-1 therapy.
A tirzepatide microdosing schedule typically begins at 0.5 to 1.25 mg weekly, well below the approved starting dose of 2.5 mg. Increases happen every two to four weeks based on tolerance and appetite control. On a slow-ramp approach, it can take four to six months to reach 5.0 mg.
The key signal your provider looks for before recommending an increase: your current dose is still producing appetite suppression, you have had minimal side effects for at least two consecutive weeks, and your weight is trending in the right direction.
When to Increase Your Microdose
Moving up too fast is what drives most of the GI problems people associate with GLP-1 medications. Moving up too slowly can mean spending months at a dose that is too low to produce meaningful progress.
Your provider watches for three things before recommending a dose increase:
- Side effects have settled. If nausea, fatigue, or GI discomfort is still showing up regularly, you stay at the current dose.
- Appetite control is weakening. Once your current dose stops keeping hunger in check consistently, it is time to consider going up.
- A plateau has held for three to four weeks despite consistent effort with food choices and activity.
Never adjust your dose on your own between provider reviews. Your medical team looks at the full picture before making that call.
Nutrition During GLP-1 Microdosing: Why the Dose Chart Is Only Part of the Story
Here is what the dosing charts do not tell you: the medication changes how your body responds to food, but it does not tell you what to eat.
At lower microdoses, appetite suppression is mild. That means the work of building better eating habits falls more heavily on you rather than on the medication. A lot of patients waste that early window because nobody explained that their body’s nutritional needs actually shift on GLP-1.
Protein is the clearest example. GLP-1 reduces appetite broadly, and patients who do not actively prioritize protein intake can lose muscle mass alongside fat. That is a real clinical concern, and it does not appear anywhere in a standard dosing chart.
The GLP-1 Nutrition Protocol™ was built around exactly this problem. It is a 7-module, 26-lesson course included free with every Telezen MD program, designed for how GLP-1 actually changes what your body needs. Most diets were not designed for GLP-1 patients. This one was.
The protocol covers protein strategy on low-appetite days, managing nausea around injection timing, what to eat when hunger returns mid-cycle, and how to tell nutritionally whether a plateau calls for a dose adjustment or a different food approach. You can explore the full microdosing program at Telezen MD.
The Part of Microdosing Most Programs Skip
Weight loss during GLP-1 microdosing is real. But for most people, keeping the weight off long term requires more than a carefully calibrated dose.
Lina Viner, co-founder of Telezen MD, built Lose It for Life™ to address the part medication cannot reach on its own: the subconscious patterns that drive overeating, emotional eating, and the familiar cycle of losing weight and regaining it.
Lose It for Life is a 10-module digital course available free to all Telezen patients. It uses The Rewire Method™, a subconscious reprogramming approach developed by Lina, to work on the beliefs and behavioral patterns that no dose change can address. Modules cover breaking the comfort-food cycle, rewriting food stories built in childhood, managing cortisol-driven cravings, and building an identity that supports lasting change rather than temporary results.
“Medical science takes the weight off. Mind science keeps it off.”
If you want to understand the full cost of the microdosing program, visit telezenmd.com/glp1-microdosing-cost.
Telezen MD also provides concierge support throughout your program. You call or text and reach a real person, not a portal message that gets answered three days later.
A GLP-1 microdosing schedule gives you a gentler path into treatment, but the dose chart is only one part of what determines your outcome. Nutrition strategy, mindset work, and consistent support matter as much as the number on the syringe.
Telezen MD pairs your prescription with The GLP-1 Nutrition Protocol™ and Lose It for Life™, the two programs built to help you get results from your medication and hold onto them. Complete your intake today.
Frequently Asked Questions
What is the starting dose for GLP-1 microdosing?
Most microdosing protocols for semaglutide start between 0.05 and 0.125 mg weekly, compared to the FDA-approved starting dose of 0.25 mg. For tirzepatide, microdosing often begins at 0.5 to 1.25 mg weekly, below the approved starting dose of 2.5 mg. Your provider sets your actual starting point based on your health history and how your body responds to treatment.
How long does it take to see results with GLP-1 microdosing?
Results take longer than with standard dosing because dose increases happen more gradually. Most patients on a microdosing schedule take three to six months to reach a standard therapeutic dose range and may see gradual weight changes throughout that period. Staying consistent with both medication and nutrition habits makes the biggest difference during that window.
Can I switch from microdosing to a standard dose later?
Yes. Many patients use microdosing as an on-ramp to standard GLP-1 therapy. Once your body has adjusted and side effects have settled at a lower dose, your provider can evaluate whether moving to a standard titration schedule fits your goals. This is a common progression, not an either-or choice.
Is GLP-1 microdosing safe?
Microdosing compounded GLP-1 medications is an off-label approach that should only be managed by a licensed provider. When medication comes from a 503A FDA-regulated pharmacy and your dosing is overseen by your medical team, the safety profile is consistent with standard GLP-1 treatment. What to avoid: sourcing medication without a prescription from unverified online vendors or DIY compounders, where purity and dosing accuracy cannot be confirmed.
Do I need to change what I eat during GLP-1 microdosing?
Yes, and especially at lower doses where appetite suppression is mild. Your body’s nutritional needs shift on GLP-1, particularly around protein. Inadequate protein during treatment can contribute to muscle loss alongside fat loss. Building nutrition habits that match how GLP-1 changes your metabolism is one of the most valuable things you can do in the microdosing phase.
How is tirzepatide microdosing different from semaglutide microdosing?
Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide acts on GLP-1 only. The dual mechanism means tirzepatide tends to produce stronger appetite suppression and, in clinical trials, greater average weight loss at max doses. It can also mean more pronounced side effects early on, which is part of why some patients and providers prefer starting tirzepatide on a gentler microdosing ramp.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. nejm.org
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. nejm.org
- Sikirica MV, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey. Diabetes Metab Syndr Obes. 2017;10:403-412. pmc.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. NDA 209637. Updated 2025. fda.gov
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. NDA 217806. Updated 2025. fda.gov
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. GLP-1 medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.
